# reload+after+2024-01-20 19:43:31.971735
address1§80 Guest Street
address2§5th Floor
city§Boston
state§MA
zip§02135
country§United States
phone§617 500 8864
website§https://www.aurabiosciences.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§70
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Elisabet  de los Pinos Ph.D.', 'age': 50, 'title': 'Founder, CEO, President & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 795300, 'exercisedValue': 0, 'unexercisedValue': 5545784}, {'maxAge': 1, 'name': 'Ms. Julie B. Feder', 'age': 53, 'title': 'CFO, Secretary & Treasurer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 505449, 'exercisedValue': 0, 'unexercisedValue': 1627206}, {'maxAge': 1, 'name': 'Dr. Mark  Plavsic D.V.M., Ph.D.', 'age': 62, 'title': 'Chief Technology Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Patrick  Nealon', 'title': 'Senior Vice President of Clinical Development Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bruce  Brown M.D.', 'title': 'Senior VP & Therapeutic Area Head of Urologic Oncology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Anthony  Daniels M.D.', 'title': 'Therapeutic Area Head of Ocular Oncology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard  Mountfield Ph.D.', 'title': 'Senior Vice President of Regulatory Affairs & Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jill  Hopkins M.D.', 'title': 'Chief Medical Officer & President of Research and Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§7
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.314
currency§USD
dateShortInterest§1702598400
forwardEps§-1.77
exchange§NGM
quoteType§EQUITY
shortName§Aura Biosciences, Inc.
longName§Aura Biosciences, Inc.
firstTradeDateEpochUtc§1635514200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§205d4b2f-04ec-3b66-84a0-9c2c5c015d78
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§19.0
targetMeanPrice§19.8
targetMedianPrice§20.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§13.682
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
